• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal
  • Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France (REMAIN)

Disease
gastroesophageal reflux disease
Drug Name
AZD3355
Generic Name
AZD3355
Sponsor
AstraZeneca
Drug Status
Discontinued
Phase
Non-Interventional Study
Start Date
Feb 5, 2009
Study Name
D9120N00013
Study Id
D9120N00013
ClinicalTrials.gov ID
NCT00842855
Recruiting Status
Closed
Protocol
Nov 5, 2008
  • D9120N00013.pdf (375 KB)
Report
May 27, 2011
  • D9120N00013.pdf (696 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013